Valerio Therapeutics is preparing to acquire Etherna Immunotherapies

Valerio Therapeutics has announced a firm offer to acquire all of the shares of Etherna Immunotherapies, a Belgian biotechnology company. This acquisition is part of Valerio's strategy to become a global leader in targeted RNA-based therapies. The integration of Etherna's mRNA and lipid nanoparticle technologies through this acquisition is strategic.

The transaction, valued at €30 million in cash and shares, requires regulatory approval and the consent of shareholders, who already hold over 70% of the shares. This merger, backed by major investors, could significantly transform Valerio, increasing its capacity to develop and manufacture innovative medicines.

This operation is being led by Gilles Besin, recently appointed CEO of Valerio, who brings 20 years of experience in the sector. Etherna's board of directors unanimously approved the offer.